-+ 0.00%
-+ 0.00%
-+ 0.00%

Anke Biotech announced that the PA3-17 injection independently developed by participating companies Bosheng Ji Pharmaceutical Technology Co., Ltd. and Bosheng Jianke Cell Technology Co., Ltd. has been accepted for clinical trial applications for the addition of “relapsed/refractory T-lymphocytic leukemia/lymphoma in children and adolescents”, and has received the administrative licensing document “Notice of Acceptance” from the State Drug Administration. The acceptance number is: CXSL2501040.

Zhitongcaijing·12/04/2025 10:17:08
Listen to the news
Anke Biotech announced that the PA3-17 injection independently developed by participating companies Bosheng Ji Pharmaceutical Technology Co., Ltd. and Bosheng Jianke Cell Technology Co., Ltd. has been accepted for clinical trial applications for the addition of “relapsed/refractory T-lymphocytic leukemia/lymphoma in children and adolescents”, and has received the administrative licensing document “Notice of Acceptance” from the State Drug Administration. The acceptance number is: CXSL2501040.